+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07686640

Phase III Trial of Short-Course Radiotherapy Followed by CAPOX Chemotherapy With or Without Iparomlimab and Tuvonralimab in pMMRMSS Locally Advanced Rectal Cancer

Led by Shandong Cancer Hospital and Institute · Updated on 2026-08-18

180

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding the drugs iparomlimab and tuvonralimab to CAPOX consolidation chemotherapy after short-course radiotherapy improves the tumor response in patients with treatment-naive, proficient mismatch repairmicrosatellite-stable pMMRMSS locally advanced rectal adenocarcinoma. This is a phase III, multicenter, randomized controlled trial comparing two treatment approaches for this type of rectal cancer. The study aims to better understand treatment effects on complete response rates, relapse-free survival, overall survival, sphincter preservation, and treatment side effects. Participants will be randomly assigned to receive short-course external-beam radiotherapy followed by either CAPOX chemotherapy combined with iparomlimab and tuvonralimab or CAPOX chemotherapy alone. The radiotherapy dose is 25 Gy given in 5 fractions over 1 week. The consolidation chemotherapy cycles last 21 days each, repeated 6 times, with oxaliplatin given intravenously on day 1 and capecitabine taken orally twice daily for 14 days. In the experimental group, iparomlimab and tuvonralimab injections are given intravenously every 21 days for 6 cycles alongside CAPOX. Participants will be monitored for tumor response through pathological assessment after surgery or clinical assessment if a Watch-and-Wait approach is followed in case of complete response. Patients with incomplete response will undergo standard surgery. Researchers will collect tissue and blood samples to explore biomarkers linked to treatment outcomes. The study also tracks survival rates, sphincter preservation, and adverse events up to 3 years after randomization, with safety monitoring extending 30 days after neoadjuvant treatment. The study lasts until July 2030.

CONDITIONS

Brief Title

Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer

Research Team

J

Jinbo Yue Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here